Type 2 diabetes is a chronic disease that continues to rise in prevalence across the globe. According to the International Diabetes Federation (IDF, 2023), over 530 million adults are currently living with diabetes, and this number is projected to reach 643 million by 2030 and 783 million by 2045. This sustained growth, driven by aging populations, sedentary lifestyles, and poor dietary habits, positions diabetes as one of the most significant public health challenges of the 21st century.
Type 2 diabetes accounts for nearly 90% of all cases, making it a key focus for healthcare systems and pharmaceutical innovation. Its progressive and systemic nature calls for long-term therapies that not only manage blood glucose levels, but also address associated complications such as cardiovascular disease and kidney damage.
Evolving Treatment Strategies: The Critical Role of SGLT2 Inhibitors
Recent years have seen the rise of more holistic and effective treatment options. Among them, SGLT2 inhibitors (sodium-glucose cotransporter 2) have gained traction for their ability to lower blood glucose by increasing its excretion through urine, working independently of insulin. This unique mechanism offers additional cardiovascular and renal benefits, as demonstrated by a growing body of clinical evidence.
As a result, SGLT2 inhibitors are now recommended in international treatment guidelines, particularly for patients at high cardiovascular risk. Their widespread adoption is driving strong global demand for high-quality active pharmaceutical ingredients (APIs).
Canagliflozin Hemihydrate: Market Positioning and Growth Potential
Within this therapeutic class, Canagliflozin Hemihydrate stands out as one of the most effective and widely prescribed options. Its robust clinical performance and broad therapeutic benefits make it a cornerstone in the treatment of type 2 diabetes.
For pharmaceutical companies, Canagliflozin represents a high-value opportunity to:
- Expand portfolios in metabolic and cardiovascular segments
- Enter high-growth emerging markets focused on chronic disease management
- Secure a reliable API with proven clinical value and rising demand
The treatment of chronic conditions like diabetes requires sustainable, long-term, and globally available solutions. API manufacturers play a pivotal role in ensuring continuous access to essential molecules across the world.
Suanfarma’s Commitment to Long-Term Therapeutic Solutions
At Suanfarma, we provide Canagliflozin Hemihydrate with a comprehensive approach tailored to today’s pharmaceutical needs:
- 98% purity for optimal efficacy and stability
- Full regulatory support across the US, Europe, Japan, Brazil, Mexico, and more
- Scalable production capacity: up to 2,500 kg/year with 3-week batch release
- Industrial availability starting Q3 2025
- Sustainable, cost-efficient manufacturing processes
We believe that supporting chronic disease treatments goes beyond API supply—it means ensuring global access, manufacturing efficiency, and clinical impact.
